Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Christina Brooks

Pain Medicine Appleton, WI Medical Doctor

NPI 1609307958 CMS profile 11338631

2400 E Capitol Dr, Appleton, WI 54911

Open in the dashboard

General payments

$14,259

138 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Brooks of Appleton, WI is reported in the CMS Open Payments database as having received $14,259 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $793 19
2024 General $1,091 23
2023 General $3,404 39
2022 General $8,970 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Brooks
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Christina Brooks were reported at $793. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Christina Brooks Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $8,970 $455 $137–$1,484 $149
2023 $3,404 $484 $128–$1,495 $160
2024 $1,091 $498 $131–$1,540 $164
2025 $793 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $6,845 65 payments
  2. Abbott Laboratories $4,231 26 payments
  3. Boston Scientific Corporation $1,378 23 payments
  4. SI-BONE, Inc. $566 4 payments
  5. SPR Therapeutics, Inc $345 8 payments
  6. Nevro Corp. $290 3 payments
  7. Vertos Medical, Inc. $287 3 payments
  8. Globus Medical, Inc. $138 1 payment
  9. Alexion Pharmaceuticals, Inc. $97 2 payments
  10. Bioventus LLC $66 2 payments
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $9,103 40 payments
  2. Food and Beverage $5,156 98 payments
Products named General payments · program years 2022–2025
  1. SYNCHROMEDII $2,546 16 payments
  2. OSTEOCOOL RF ABLATION SYSTEM $2,137 22 payments
  3. PROCLAIM Neuromodulation $1,649 9 payments
  4. INTELLIS ADAPTIVESTIM $1,279 17 payments
  5. PROCLAIM Neuromodulation $1,211 8 payments
  6. PRODIGY $1,114 4 payments
  7. Superion Indirect Decompression System $927 6 payments
  8. VANTA ADAPTIVESTIM $866 9 payments
  9. SPRINT PNS System $345 8 payments
  10. mild Device Kit $287 3 payments
  11. Other $1,216 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

260

Median for Pain Management: 951

Drug cost

$2,989

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 38 $970
Duloxetine Hcl Generic 45 $676
Gabapentin Generic 44 $515
Tizanidine Hcl Generic 38 $215
Methocarbamol Generic 23 $196
Meloxicam Generic 24 $160
Cyclobenzaprine Hcl Generic 20 $126
Diclofenac Sodium Generic 11 $77
Cephalexin Generic 17 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$45,709

Of which drugs: $3,048

Medicare patients

144

Average age 71

Services billed

2,945

88 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Depression 40%
Diabetes 31%
Chronic kidney disease 26%
Ischemic heart disease 23%
COPD 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 1,120 $116

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record